Literature DB >> 19671939

Cytologic phenotypes of B-cell acute lymphoblastic leukemia-a single center study.

Asghar Ramyar1, Masoud Shafiei, Nima Rezaei, Hossein Asgarian-Omran, Shadi Abdar Esfahani, Kasra Moazzami, Abdolfattah Sarafnejad, Asghar Aghamohammadi.   

Abstract

Acute lymphoblastic leukemia (ALL) is a malignant disorder of lymphoid precursor cells, which could be classified according to morphological and cytochemical methods as well as immunophenotyping. Twenty patients with ALL, who had been referred to the Children's Medical Center Hospital, during the year 2007, were enrolled in this study in order to evaluate the morphologic and immunophenotypic profile of these patients. Cytologic analysis of blood and bone marrow samples revealed that the frequency of ALL-L1 was 70%, followed by ALL-L2 and ALL-L3. The onset age of the patients with ALL-L1 was significantly lower than the patients with L2/L3. Severe anemia was significantly detected more in L1 group. Flow cytometic study of bone marrow showed that 10 cases had Pre-B1 ALL and 7 cases had Pre-B2 ALL, while three cases had Pro-B ALL. Comparisons of the characteristics and clinical manifestations among these groups did not show any appreciable difference. There were an increase percentage of CD20+ cells and a decrease CD10+ cells in pre-B2 group in comparison with pre-B1 group. Fifteen patients were in standard risk and five were in high risk. Although standard risk patients were more common in the group of pre-B1, this was not significant. Our results confirm the previous reports indicating heterogeneity of ALL. Immunophenotyping is not the only diagnostic test of importance, while morphological assessment still can be used in the diagnosis and classification of the disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19671939     DOI: 08.02/ijaai.99106

Source DB:  PubMed          Journal:  Iran J Allergy Asthma Immunol        ISSN: 1735-1502            Impact factor:   1.464


  2 in total

1.  TPEN selectively eliminates lymphoblastic B cells from bone marrow pediatric acute lymphoblastic leukemia patients.

Authors:  M Mendivil-Perez; C Velez-Pardo; L M Quiroz-Duque; A Restrepo-Rincon; N A Valencia-Zuluaga; Marlene Jimenez-Del-Rio
Journal:  Biometals       Date:  2022-05-30       Impact factor: 3.378

2.  The Expression and Prognostic Impact of CD95 Death Receptor and CD20, CD34 and CD44 Differentiation Markers in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Fatemeh M Kamazani; Gholamreza Bahoush-Mehdiabadi; Mahnaz Aghaeipour; Shahram Vaeli; Zahra Amirghofran
Journal:  Iran J Pediatr       Date:  2014-05-21       Impact factor: 0.364

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.